drug
ZOLEDRONIC ACID
Marketedupdated 3mo agoby Avenacy Inc
Approvedcommunity read0 votes
🐶 often sniffed alongside
top 3all catalysts(22)
approval · 22
Apr 16, 2007
approval
RECLAST (ZOLEDRONIC ACID) — FDA approval
ZOLEDRONIC ACID
→
Jun 3, 2008
approval
RECLAST (ZOLEDRONIC ACID) — FDA approval
ZOLEDRONIC ACID
→
Dec 19, 2008
approval
RECLAST (ZOLEDRONIC ACID) — FDA approval
ZOLEDRONIC ACID
→
Mar 13, 2009
approval
RECLAST (ZOLEDRONIC ACID) — FDA approval
ZOLEDRONIC ACID
→
May 29, 2009
approval
RECLAST (ZOLEDRONIC ACID) — FDA approval
ZOLEDRONIC ACID
→
Jan 25, 2011
approval
RECLAST (ZOLEDRONIC ACID) — FDA approval
ZOLEDRONIC ACID
→
Mar 8, 2011
approval
RECLAST (ZOLEDRONIC ACID) — FDA approval
ZOLEDRONIC ACID
→
Aug 15, 2011
approval
RECLAST (ZOLEDRONIC ACID) — FDA approval
ZOLEDRONIC ACID
→
Aug 31, 2011
approval
RECLAST (ZOLEDRONIC ACID) — FDA approval
ZOLEDRONIC ACID
→
Apr 19, 2013
approval
RECLAST (ZOLEDRONIC ACID) — FDA approval
ZOLEDRONIC ACID
→
Jul 23, 2013
approval
RECLAST (ZOLEDRONIC ACID) — FDA approval
ZOLEDRONIC ACID
→
Sep 17, 2013
approval
RECLAST (ZOLEDRONIC ACID) — FDA approval
ZOLEDRONIC ACID
→
May 13, 2014
approval
RECLAST (ZOLEDRONIC ACID) — FDA approval
ZOLEDRONIC ACID
→
Jun 17, 2014
approval
RECLAST (ZOLEDRONIC ACID) — FDA approval
ZOLEDRONIC ACID
→
Jan 30, 2015
approval
RECLAST (ZOLEDRONIC ACID) — FDA approval
ZOLEDRONIC ACID
→
Apr 16, 2015
approval
RECLAST (ZOLEDRONIC ACID) — FDA approval
ZOLEDRONIC ACID
→
Apr 14, 2016
approval
RECLAST (ZOLEDRONIC ACID) — FDA approval
ZOLEDRONIC ACID
→
May 24, 2016
approval
RECLAST (ZOLEDRONIC ACID) — FDA approval
ZOLEDRONIC ACID
→
Jul 7, 2017
approval
RECLAST (ZOLEDRONIC ACID) — FDA approval
ZOLEDRONIC ACID
→
Apr 29, 2020
approval
RECLAST (ZOLEDRONIC ACID) — FDA approval
ZOLEDRONIC ACID
→
Feb 3, 2026
approval
RECLAST (ZOLEDRONIC ACID) — FDA approval
ZOLEDRONIC ACID
→
Feb 5, 2026
approval
ZOLEDRONIC ACID — FDA approval
ZOLEDRONIC ACID
→
Trials studying ZOLEDRONIC ACID
- phase3Ixazomib Citrate, Lenalidomide, Dexamethasone, and Zoledronic Acid or Zoledronic Acid Alone After Radiation Therapy in Treating Patients With Solitary Plasmacytoma of Bone
- phase2Zunsemetinib in Combination With Capecitabine in Patients With Hormone Receptor-Positive and HER2-Negative Metastatic Breast Cancer With Bone Metastasis
- phase3Effects of Romosozumab on Bone Density in Women With Anorexia Nervosa
- phase2Treatment With Dinutuximab Beta, Zoledronic Acid and Low-dose Interleukin (IL-2) in Patients With Leiomyosarcoma
- phase3Combined Chemotherapy With or Without Zoledronic Acid for Patients With Osteosarcoma
- phase1Safety and Activity of IMAB362 in Combination With Zoledronic Acid and Interleukin-2 in CLDN18.2-positive Gastric Cancer
- —Study to Investigate the Efficacy and Safety After Administration of Daewoong Zoledronic Acid for the Purpose of Treatment or Prevention of Osteoporosis
- phase2Bisphosphonates for Prevention of Post-Denosumab Bone Loss
Patent cliff
source: FDA Orange Bookfirst barrier falls
Feb 5, 2028
~1.5 years out
Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.
patents (3)
- Aug 5, 2028patentUS 7932241*PED2.0y
- Feb 5, 2028formulationUS 79322411.5y
- Feb 5, 2028formulationUS 79322411.5y
News(0)
no news has mentioned this drug yet
Data sources
last refreshed 1h ago
Found something off?
comments(0)
5-min edit window · permanent after that